NHS to offer second MenB vaccine after deadly Kent outbreak
NHS to Offer Second MenB Vaccine Following Kent Outbreak
Next week, nearly 12,000 individuals who received meningitis B vaccinations during a recent outbreak in Kent will be invited for a second dose. The outbreak led to two deaths and 19 confirmed cases of the disease. The initial vaccination drive targeted people who might have been exposed, such as students and pupils from local schools in the region.
Targeted Rollout and Eligibility
Vaccination centers are launching in Canterbury, Faversham, and Ashford, with eligible individuals able to book appointments through an online system. Those offered the second dose include students residing in university accommodations in Kent and attendees of a nightclub linked to the outbreak. NHS Kent and Medway has announced that multiple clinics will be available, with booking details to be released starting Monday.
“The outbreak was unprecedented due to the rapid spread among people in a short period.”
Health Secretary Wes Streeting emphasized the unusual nature of the incident, noting the swift transmission of the infection. A 21-year-old university student, whose identity remains private, and sixth form pupil Juliette Kenny both succumbed to the illness. Over 100 others required hospital treatment for related complications.
The UK Health Security Agency (UKHSA) initiated a national incident declaration to streamline the distribution of antibiotics and other resources. The program began with students in Kent university halls before expanding to patrons of Club Chemistry, where the outbreak is believed to have started. Later, certain sixth form students at schools with confirmed cases were also added to the list.
Preventative antibiotics were administered to a broader group, with long lines forming at the University of Kent over several days as people awaited treatment. The MenB vaccine, which targets most meningococcal group B strains in the UK, was introduced as a routine immunization in 2015 for infants and young children. At that time, UK health advisors concluded that a catch-up campaign for teenagers was not cost-effective, opting instead for the MenACWY vaccine, which covers four bacterial types but excludes MenB.
Following the Kent outbreak, Streeting requested a reassessment of the decision to exclude teenagers from MenB vaccination programs. This review comes amid concerns that the recent incident highlights gaps in current immunization strategies. The second dose must be administered at least four weeks after the first, though delays are permissible.
